Warning Letter — Bella’s Nutri Shop Inc.
The FDA issued a Warning Letter to Bella’s Nutri Shop Inc. following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects Bella’s Nutri Shop Inc. and regulatory, quality, and marketing departments responsible for product labeling and therapeutic claims.
The involvement of CDER suggests the FDA may have identified products being marketed with drug-like therapeutic claims or containing active ingredients that classify the products as unapproved new drugs. This type of enforcement indicates a failure to maintain the distinction between dietary supplements and regulated medicinal products, posing significant litigation and market withdrawal risks.
Conduct a comprehensive review of all digital and physical marketing collateral to ensure no therapeutic or disease-related claims are being made for products marketed as supplements. Review product positioning to confirm they meet the legal definition of their intended category without crossing into unapproved drug territory.
FDA Warning Letter issued to: Bella’s Nutri Shop Inc.. 10/26/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bellas-nutri-shop-inc-737491-10262026
Open in openFDA / FDA.gov